Dyslipidemia in Transplant Patients: Which Therapy?
Gabriella Iannuzzo, Gianluigi Cuomo, Anna Di Lorenzo, Maria Tripaldella, Vania Mallardo, Paola Iaccarino Idelson, Caterina Sagnelli, Antonello Sica, Massimiliano Creta, Javier Baltar, Felice Crocetto, Alessandro Bresciani, Marco Gentile, Armando Calogero, Francesco Giallauria
Abstract
Cardiovascular disease is the most important cause of death worldwide in recent years; an increasing trend is also shown in organ transplant patients subjected to immunosuppressive therapies, in which cardiovascular diseases represent one of the most frequent causes of long-term mortality. This is also linked to immunosuppressant-induced dyslipidemia, which occurs in 27 to 71% of organ transplant recipients. The aim of this review is to clarify the pathophysiological mechanisms underlying dyslipidemia in patients treated with immunosuppressants to identify immunosuppressive therapies which do not cause dyslipidemia or therapeutic pathways effective in reducing hypercholesterolemia, hypertriglyceridemia, or both, without further adverse events.